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Objectives
• Rural (US) TB epidemiology indicates 
treating LTBI is an appropriate strategy
• Describe Screening for LTBI: TST and 
IGRA
• Describe current treatment for LTBI
• Describe monitoring recommendations
TB Nomenclature
• Latent TB Infection (~90% TB infections): 
– Positive TST (or IGRA eg, QFT-G)
– No symptoms
– Negative or chronic CXR changes
– Can not transmit disease to others.
• Active TB Infection (~10% TB infections): 
– TST (or IGRA) may be positive
– Symptoms present
– CXR changes & sputum smear positive in most cases
– Disease transmission to others
• Treatment for both latent and active infections
• Avoid terms: Prophylaxis, Preventive therapy
TB Pathogenesis
Progression to Disease
3-4% First Year
1-2% Second Year
~0.1% per year thereafter
Infection (LTBI)
Disease
(Active Infection)
No
Active
Disease
(~90%)
Epidemiology of Tuberculosis
TB in Foreign-Born Immigrants to US
• Proportion of TB cases foreign-born increased from 
<25% to 57% (1986-2006)
• US-born TB cases decreased by 45% (1993-2006)
• ~70% MDR TB occur among Foreign-born
– Anticipate XDR TB & TDR TB 
• SE Asians, Sub-Saharan Africans, & Latin Americans
• Concentrated in NY, NJ, Ca, Fl, IL, Tx
• Active cases most often arise from prior infection
• ~55% occur within 5 yrs of immigration
 2 yrs in US 75/100,000 
> 2 yrs in US 16/100,000
CDC; Cain et al: JAMA 2008
Foreign-Born  US 
TB Cases & Case Rates vs. Years in US
Cain et al: JAMA 2008
~30% Foreign-born coming 
into US unscreened…
Refugee & Immigrant TB Screening
• Within Country of Origin
– Adults: Evaluated for Active TB only
– Children (<15 yrs) & TB contacts screened (TST) in 
some countries but no LTBI Rx
• Arrival within US
– TB Suspects are expected to f/u w/ local health dept 
(not mandated)
– Applicants for adjustment of status evaluated for LTBI 
(Rx not mandated)
• Not evaluated…Estimates ~30%
– Visitors, Temp Workers, Undocumented
– Student visa 
Immigration process doesn’t deal with LTBI for you…
“Tuberculosis is a social disease with 
medical implications”
–Sir William Osler
How do Rural TB rates compare to 
the National TB rates?
US vs. Foreign-Born TB Cases – Iowa 2012
9
37US:   3.2 /100,000
Iowa: 1.5 /100,000
~1/yr drug resistant 
Focus of TB Control in the US:
Targeted Testing & Rx for LTBI
• Few cases due to transmission from other 
active cases ( HIV related cases)
• High rates of TB among foreign-born 
immigrants to US (including rural locales) 
from high incident countries
• “Targeted tuberculin testing” is the theme of 
the LTBI guidelines
• One of the main targets must be the foreign-
born immigrants from high incident countries  
Relative TB Risk
Risk Factor
Risk Estimate
(vs. control w/ +TST)
Advanced HIV 9.9
Anti-TNF Rx 7.9
Old, healed TB 5.2
Diabetes mellitus 3.1
Tobacco abuse 2.7
Chronic Renal Failure 2.4
Silicosis 1.7
Underweight (10% < IBW) 1.6
Gastrectomy 1.4
Horsburgh. NEJM 2004; Gossec. Ann Rheum Dis 2009
Jeon. PLoS Med 2008; Lin. PLoS Med 2007
Targeted TB Testing
Decision to Test = Decision to Treat
• Patients at highest risk for progression to 
active TB
• Patients with medical conditions that 
increase risk for active TB
• Patients in whom active TB is more 
prevalent
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Targeted TB Testing
Decision to Test = Decision to Treat
Patients at highest risk for progression to active TB
• HIV infection, or risk factors for HIV infection
• Receiving TNF antagonist for RA or Crohn’s 
• Fibrotic lesion on CXR c/w prior pulmonary TB
• Close contact of persons with infectious TB 
(e.g, pulmonary, laryngeal TB)
• New TB infection (TST conversion within prior 2 
years)
• IV drug abuser (HIV negative)
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Targeted TB Testing
Decision to Test = Decision to Treat
Medical conditions  risk for progression to active TB
• Diabetes mellitus
• Tobacco abuse (NEW)
• Silicosis 
• Jejunoilieal bypass surgery or gastrectomy
• Solid organ transplant (e.g. renal, heart)
• Chronic renal failure/hemodialysis
• Head/neck carcinoma 
• Hematologic malignancies (e.g. leukemia, Hodgkin’s)
• Immunosuppressed, particularly steroid treatment (15 
mg/day,  1 month)
• Substantial weight loss: >10% ideal body weight
Targeted TB Testing
Decision to Test = Decision to Treat
• Patients at highest risk for progression to 
active TB
• Patients with non-HIV medical conditions 
that increase risk for active TB
• Patients in whom active TB is more 
prevalent
Targeted Skin Testing
Decision to Test = Decision to Treat
Patients in whom active TB is more prevalent
• Recent arrivals (< 5 years) from high TB prevalence 
countries (Africa, SE Asia, Pacific Isles, Latino, E. 
Europe, Russia)
• Resident or employee of high-risk congregate settings: 
prisons/jails, nursing homes/other long term facilities, 
hospitals/other health care facilities, residential 
facilities for AIDS patients, and homeless shelters
• Mycobacteriology lab workers
Case S. B.
• 56 yo female
• Asymptomatic
• TST+ (estranged husband had TB 20 
years ago)
• On no drugs, no HIV risk factors, no EtOH
• Chest x-ray unremarkable
What is the diagnosis? 
Latent TB Infection (LTBI)
New technology replacing old…
Mantoux Tuberculin Skin Test (TST)
• Standard (old) method of skin testing for M. 
tuberculosis infection 
• Produces delayed-type hypersensitivity reaction
• TST is useful for..
– Detecting LTBI
– Contact investigation: Determining how 
many people in a group are infected 
– Evaluating persons who have symptoms of 
active TB
Administering the TST
• Inject 0.1 ml of 5 TU PPD 
tuberculin solution 
intradermally on volar 
surface of lower arm 
using a 27-gauge needle
• Produce a wheal 6 to 10 
mm in diameter
•
Low (Old) Tech…TST
Delayed-type Hypersensitivity Reaction @ 48-72 hrs
• Positive: 18 mm Induration
• A positive test may be measured up to 7 days out
• A negative reaction can be read accurately @ 48-72 hrs
Reading a TST
• Measure induration, not erythema by 48 to 72 
hours
• Record induration size in millimeters, in addition to 
interpretation (“negative” or “positive”)
• Ensure trained health care professional measures 
& interprets the TST
• Educate patient & family about the significance of a 
positive test
TST Interpretation
Positive classification based on pre-test probability of TB:
 5 mm = positive
• HIV positive
• Household or close contact to patient with infectious, active TB
• CXR consistent with old/healed TB
• Organ transplant or other immunosuppressed patient
 10 mm = positive
• Foreign born (e.g. Africa, SE Asia, Hispanic, India, China, E Europe)
• IV drug abusers
• Residents or employee of high risk congregate setting
• Non-immunosuppressive medical conditions known to increase risk 
of active TB
• Mycobacteriology lab workers
 15 mm = positive
• Persons in regions of low TB incidence
Limitations for TST
• Interpretation variability; False positives: NTM, BCG…
• BCG Vaccine effect on TST Interpretation
– Induces 3-19 mm TST reaction in 1st few mos.
• Reaction wanes significantly by 10 years
• Reaction size does not correlate with protection
– Positive TST most likely due to TB infection:
• Persons from regions of high TB prevalence (eg. hispanic, asian)
• Large reaction (>15 mm)
– Prior BCG, should be Tested and Treated if positive
• Booster Phenomenon
– False negative TST, becomes positive as a result of skin testing
– Most common situations:
• Initial TB infection many years previous
• Prior BCG immunization
– Two Step Skin Testing (TST x 2, one week apart)
• Elderly nursing home population
• Prior BCG immunization
LTBI Testing Upgrade…
Interferon Gamma Release Assay (IGRA)
Measures interferon-gamma (IFN-) released by 
lymphocytes in response to specific TB antigens: 
ESAT-6, CFP-10
• QuantiFERON® Family:
– QuantiFERON® -TB test 1999
– QuantiFERON® - TB Gold 2005
– QuantiFERON® - TB Gold In-Tube (GIT) 2007
Added 3rd antigen TB7.7 (RD4) & travel time
• T-Spot.TB® Aug 2008:
TST vs IGRA
Antigen
Presenting
Cell
Memory
T-Cell
Presentation of TB antigens
• TST (Multiple = PPD)
• IGRA (Specific = ESAT-6, CFP-10)
IFN-
IFN-
IL-8, etc.
IL-8, etc.
TNF-
TNF-
Andersen P et al: Lancet 2000;356:1099
TST
IGRA
IGRA Results include control wells
• Negative (Nil) – no antigen (subtract from pt value)
• Positive – mitogen stimulation 
IGRA vs TST
IGRA
• In vitro
• Specific antigens
• Unaffected by BCG
• No boosting
• One patient visit
• No inter-reader variability
• One standard result for all
TST
• In vivo
• Multiple antigens
• BCG affects results
• Boost occurs
• Two pt visits
• Inter-reader variability
• Different thresholds 
based on risk
QFT vs T-Spot.TB
+ Control   -
QFT-TB Gold in Tube:
Ag
Tube
• Quantiferon TB (QFT):
Whole blood incubated w/ TB
specific antigens. ELISA 
measures IFN- release
• T-Spot.TB:
Lymphocytes (T) incubated w/
specific antigens. ELISPOT-
method counts IFN-
releasing cells
IGRA Interpretation
Positive Negative
Gray 
Zone Indeterminate
QFT-TB 
Gold & 
IT version
0.35* <0.35* None
Controls fail:
•High Nil
•Mitogen  
response
T Spot.TB 8 spots*
<8 
spots*
5-7 
spots* Same as above
*TB Ag – Nil, assuming appropriate control response
IGRA CDC Guidelines 2010
• IGRA may substitute for TST
• IGRA preferred:
– BCG vaccinated persons
– Clients unlikely to return for TST reading
– Low risk persons
• TST preferred in children <5
• Clinical judgment required when interpreting 
IGRA among immunosuppressed, children <5, 
& TB suspects
• Lab should be reporting quantitative results
Indeterminate IGRA Results
• Poor response to mitogen that resolves with
repeat assay
- Delayed specimen processing
- Technical errors
• Persistent poor response to mitogen
- Anergy from immunosuppression
- May occur in healthy persons
• High background IFN-γ levels (high NIL response)
- Often persistent, reasons unclear
- IGRA not useful
Interpreting IGRA Results
• Contact investigation: If initial IGRA negative, Repeat 
test at 8-10 wks as one would with TST
• IGRA conversion = change from neg to positive
• Indeterminate result: Repeat IGRA or do nothing 
(don’t recommend TST generally)
Areas of uncertainty:
• Quantification of IGRA conversion (serial testing)
• Possible quantitative assessment of Rx response
Host Factors Creating False Negative 
TST & IGRA
• HIV (low CD4, no HART)
• <10 wks since TB infection 
• Other infections (viral, fungal, bacterial)
• Lymphoma
• Live virus vaccination (eg, measles, smallpox)
• Immunosuppressive Rx
• Overwhelming TB (eg, miliary TB)
• Age (newborn, very old)
TST False Positives
• Cross reaction w/ NTM or BCG 
• Immediate hypersensitivity misinterpreted as positive
• TST product switch (Tubersol vs Aplisol)
IGRA False Positives
• Cross reaction NTM: M kansasii, M szulgai, & 
M marinum
• Product failure such as endotoxin traces in tubes
• Lab error
Can IGRA Replace TST?
• Contact investigation: YES
• BCG vaccine Hx: YES
• Low risk person: yes
• Screening homeless & other unreliable 
persons: YES
• Serial Testing: Yes, but…
Real Life with IGRA
• Significant reduction in positive rate vs TST
• Increased frequency of retesting
• Serial testing issues:
– Unexpected positives that require further review 
(eg, repeat testing, assessing quantitative results)
– “Wobblers” = results hovering around cut point
LTBI: TST & IGRA  Gospel
• Reassess TB risk factors
• Review symptoms
• Review CXR… evidence suggest old TB 
(Upper lobe fibrosis, Gohn lesion, Hilar Ca++)
• LTBI Rx decision should be based on 
complete certainty that active TB not present 
Key Recent References
CDC. Updated Guidelines for Using IGRAs to
detect M tuberculosis infection, US 2010. MMWR
Recommendations and Reports June 25, 2010
Pai M et al. Systematic Review: T-Cell–based 
Assays for the Diagnosis of Latent TB Infection: 
An Update. Ann Intern Med 2008; 149:177-184.
Is This Really True?
• Apples, not Caffeine, are more efficient at 
waking you up in the morning
• You burn more calories sleeping than you 
do watching TB
• Donkeys kill more people annually than 
plane crashes and/or shark attacks…
So watch your ASS…
Tuberculosis Screening Flowchart
Evaluate for 
active TB
At-risk person
TST or IGRA & symptom review
Negative Positive
Chest x-ray
Normal Abnormal
Treatment
not indicated
Potential 
candidate for 
Rx of latent TB
…Back to SB, the case of LTBI
• Obtained:
TST (Mantoux) Positive
Chest x-ray Negative
• Do you need sputum smear and culture?
Only if suspicious for active disease
Not necessary in asymptomatic patient, 
positive TST, normal CXR
What Treatment for S. B.?
Optimal LTBI Rx…
• Short as possible to enhance completion 
rates (programmatic advantages)
• Minimally toxic
Treatment of Latent TB Infection
HIV Neg. & Pos. Adults
(Dept of Public Health provides meds)
1. Daily INH for 9 months (270 doses w/in 12 mos)*,+
2. Daily INH for 6 months (100 doses w/in 9 mos)+
Exclude any w/ old healed fibrotic TB lesions on CXR
3. 1*,+ or 2+ above, administered as DOT, twice weekly
76 doses w/in 12 months or 52 doses w/in 9 months
4. Daily rifampin for 4 months (120 doses w/in 6 m)
Alternative for those who are known contacts with INH 
resistant TB or INH not feasible 
Completion = Total # doses, not duration alone
If > 2 month interruption, re-evaluate for active TB before 
restarting
ATS/CDC/IDSA 5/2000; Update 8/2003
*Recommended for children < 18 years
+Recommended for pregnant women. 
TB Case Rates vs. 
No. of Months INH Treatment (Bethal Data)
Comstock GW: Int J Tuberc Lung Dis 1999
Even Shorter Treatment = Reality…
• New regimen: INH 900 mg plus Rifapentine 900 
mg weekly x 3 months (12 doses, DOT)
• Open Label, Randomized Noninferiority trial 2011
– New regimen (DOT) vs INH x 9 mos (not DOT)
– N ~ 8000 US & Canada x 33 mos (few HIV, children)
– Target population: TST converters & +TST old healed
TB chest x-ray
– Result: New Regimen equivalent to 9 mos INH 
• Drug d/c d/t adverse events 4.9 vs 3.7%
• Increased hypersensitivity (New) vs hepatotoxicity (INHx9)
• Trend toward New regimen better than INHx9
– New Regimen group: TB rate ~50% lower
– Rx completion rate 82% vs 69% 
Sterling TR et al. NEJM 2011;365:2155-66
New Regimen vs INHx9
Sterling TR et al. NEJM 2011;365:2155-66
Real World Recommendation
• New Regimen (DOT) does not replace INHx9, but 
equal option for Rx LTBI
• (Iowa) Dept Public Health provides INHx9 at no 
cost for anyone diagnosed w/ LTBI
• IDPH agrees New Regimen equivalent to INHx9 
– New Regimen costs 10x the standard INHx9 regimen 
– IDPH able to cover high cost of New Regimen (not DOT)
– Policy for your state?
• New Regimen not recommended for the following:
– Child <2
– HIV/AIDS taking HART
– Pregnant women 
– Contacts of INH &/or Rif resistant TB
Real World Dosing
• INH: 900 mg max for those ≥ 60 kg or
15 mg/kg rounded up to the nearest 100 mg
Formulations: 300 & 100 mg tabs 
• Rifapentine: 900 mg max for ≥ 50 kg 
10.0–14.0 kg 300 mg 
14.1–25.0 kg 450 mg 
25.1–32.0 kg 600 mg 
32.1–49.9 kg 750 mg 
Formulation: 150 mg tabs (others in development)
• INH-Rifapentine combo being developed
Rifamycins Better Than INH? 
• INH monotherapy (6 or 9 mos) plagued by low 
completion rates, programmatic challenges & 
hepatotoxicity
From > 20 yrs of studies (~1500 trials), 53 RCTs 
LTBI Rx systematically selected & reviewed
• Each included relative efficacy & adverse events 
• Applied Bayesian network meta-analysis
[Allows comparison two distinct Rx regimens 
when no trials directly compare them]
Stagg et al. Ann Int Med 2014;161:419-26
LTBI Rx: Rifamycins Better Than INH? 
Comparison to standard INH monotherapy:
• Rifampin x3-4 months ranked highly for both 
efficacy & hepatoxicity
• INH & Rifampin x3-4 months also ranked well
• INH & Rifabutin trended well but data NS
• Surprise: INH & Rifapentine not as well as 
above
Stagg et al. Ann Int Med 2014;161:419-26
Regimens containing rifamycins more effective alternative?
More Real Data Coming
• HALT trial: Evaluates Non-DOT Rifapentine vs 
INH monotherapy
• CDC trial: INH x 9 mos vs Rifampin x 4 mos
Treatment for S.B.
• INH daily x 9 months
• County public health department 
supervised treatment:
– PHN performed Clinical Monitoring
– 30 day supply aliquots of INH provided 
– Completed 9 months w/in 9 months
Summary Points
• Screen persons at high risk for TB (eg, foreign born)
• Seek to distinguish active vs. latent TB infection 
• LTBI diagnosis reviewed
– Decision to test = Decision to treat!
– Highest risk subgroups identified
• Role for IGRA: QFT-Gold, T-Spot.TB
• LTBI treatment update
– Can be shortened to 3 months (INH/rifapentine x 12 doses)
– Data re-evaluation  Rifamycin better than INH?
• (Iowa) Department of Public Health provides TB Rx 
at no cost to patient
Monitoring on INH Treatment
• Educate the patient 
– Liver disease symptoms & signs 
– Stop meds until contact made with health care
• The critical element for preventing INH toxicity is
Clinical monitoring…PHN 
– Absolutely necessary to do, absolutely necessary to do 
well & absolutely necessary to document well.
• LFTs (ALT, AST) at baseline in selected cases 
– Hx of liver disease, EtOH, pregnancy, HIV
– Repeat monthly if abnormal at baseline, symptomatic, or 
pregnant
– Stop meds:
• Symptomatic, LFTs 3x upper limit of normal (ULN)
• Asymptomatic, LFTs 5x
ATS/CDC/IDSA 5/2000
Clinical Monitoring
• Instruct patient to report following adverse drug 
reactions (ADRs):
– Rash
– Anorexia, nausea, vomiting, or pain in RUQ
– Fatigue or weakness
– Dark urine
– Persistent numbness in hands or feet
• Monthly visits should include review of:
– Rationale for treatment
– Adherence to therapy
– Symptoms consistent with ADR(s)
– Plans to continue treatment
Liver Safety Issues for INH
• Deaths from INH hepatitis in 1960s
• 1971-72 PHS Study (14,000 pts)
– 1% overall rate of INH related hepatitis
– Age related increase 
• 0.3% (<35)
• 2.3% (>50)
– 4x increase a/w EtOH
– 8 deaths due to INH hepatitis
• Review of PHS data (Comstock JAMA 1986)
– 7/8 deaths occurred in Baltimore
– Death certificate review: XS deaths due to cirrhosis in 1972
– Unidentified co-factor related to cluster of cirrhosis cases ?
• Subsequent studies: risk is lower
Latest CDC Data on INH Liver Toxicity
• SAEs during LTBI Rx, 2004-2008
• 17 patients with SAEs, all hepatotoxicity
– 2 children < 15 yrs of age; Adults median age 39
– One patient HIV seropositive for Hep C, HIV
– 5/17 liver transplant (one child), 5/17 died (one transplant)
• 10/17 patients with CDC on-site investigation
 Prescribers followed ATS/CDC guidelines for Clinical Monitoring
 Symptoms 1-7 months after INH started
 Fatigue, nausea, abdominal pain in 7 patients who waited for 
jaundice to seek medical attention
 2 patients INH discontinued within 3 days of symptoms, 8 stopped at 
least one week after symptom onset; all after medical instruction
• Death & liver transplantation ~1/150,000 - 1/220,000
• SAEs idiosyncratic reaction, independent of dosing, possible 
anytime during treatment, can occur in children
MMWR 2010 59(08):224-229
Deaths from INH Hepatitis
• Rates in women increased
– Pregnancy & immediate post-partum period (3 mos)
(Snider DE et al: ARRD 1992; Franks et al: Pub Health Rep 1989)
• Concurrent acetaminophen questionable
(Murphy et al: Ann Int Med 1990; Burk et al: Res Comm. Chem Path Pharm 1990)
• INH death rate reduced by Clinical Monitoring
– Stopping INH at symptom onset reduces deaths
(Moulding TS, et al: ARRD 1989)
– 7/8 liver transplants for INH hepatitis: Pts 
continued INH >10 d beyond symptom onset
(CDC: MMWR 1993)
Safety Issues for INH:
Current Practice Outcomes
• Most PHD practice Clinical Monitoring vs. biochemical 
monitoring
• Clinical Monitoring: 
– Educate for Rx related ADRs & Reviews adherence
– Stop INH if any question until consult with clinician
– CDC: “Medical providers should emphasize to patients that 
INH treatment should be stopped immediately upon the 
earliest onset of symptoms (e.g. excess fatigue, nausea, 
vomiting, abdominal pain, or jaundice), even before a clinical 
evaluation has been conducted, and that initial symptoms 
might be subtle and might not include jaundice.”
Monitoring on Treatment
• Educate the patient 
– Liver disease symptoms & signs 
– Stop meds until contact made with health care
• Clinical monitoring monthly…PHN
• LFTs (ALT, AST) at baseline in selected cases 
– Hx of liver disease, EtOH, pregnancy, HIV
– Repeat monthly if abnormal at baseline, symptomatic, or 
pregnant
– Stop meds:
• Symptomatic, LFTs 3x upper limits of normal (ULN)
• Asymptomatic, LFTs 5x ULN
ATS/CDC/IDSA 5/2000
More Case Examples & 
Discussion
Factors Causing False-Negative TST
• Anergy = Weakened immune system  Inability 
to react to TST 
– Anergy testing utility in TST-negative persons not 
demonstrated in clinical trials
• New TB infection (eg, 2-10 weeks post exposure)
• Newborns
• Live virus vaccination (eg, measles, smallpox) 
suppresses TST response
• Overwhelming disease (eg, miliary TB)
• Poor TST administration technique 
How Should Immunosuppressed 
Persons at Risk for TB Be Managed?
Empiric treatment for LTBI even when TST or 
IGRA neg on repeat testing 8-10 weeks after 
exposure
• Advanced HIV infected contacts
• Children < 5 years who are contacts
• Contacts with other causes of immunosuppresion
• Persons who are to receive treatment with TNF 
alpha antagonists
TNF Antagonists
• Block TNF activity which is required for granuloma 
formation & containment of M tuberculosis
• Used for RA, Crohn’s disease, Psoriasis and a variety 
of other immune mediated diseases
Remicaid        (inflixamab)
Embril            (entanercept)
Humira           (adalimumab)
Cimzia            (certolizumab)
• Patients should be evaluated for LTBI w/ IGRA or TST
• Treatment of LTBI should be initiated prior to therapy
Questions Remain
• Unknown
– Does treatment of LTBI need to be completed prior to 
use of TNF- antagonist?
• Unknown
– Does a person at risk of TB who is TST negative need 
to be treated? 
• Consider treatment of high risk TST negative patients
• No need to continue INH after completion 
of treatment for LTBI
Case 2
• 36-year-old Native American female
• History of diabetes
• 35 weeks pregnant
• TST = 18 mm of induration
• No symptoms of TB disease
• CXR, CBC, LFTs normal
• No known contact with TB patient
Case 2
Questions
1. What are this patient’s risk factors for 
TB infection or disease?
2. What is the appropriate management 
for this patient?
Case 2
Discussion of risk factors
• Persons with diabetes mellitus are 2 to 4 
times more likely to develop TB disease 
than those without diabetes 
• Risk may be higher in insulin-dependent 
diabetics and those with poorly controlled 
diabetes
Case 2
Discussion of management
• Pregnancy has minimal influence on the 
pathogenesis of TB or the likelihood of LTBI 
progressing to disease
• Pregnant women should be targeted for TB 
testing only if they have specific risk factors for 
LTBI or progression to disease
• Some experts prefer to delay treatment until after 
the early postpartum period, unless the woman has 
recent TB infection or HIV infection
Case 3
• 41-year-old Hispanic male 
• Moved to U.S. from Mexico 4 years ago
• Known contact of infectious TB case
• TST = 5 mm of induration
• 3 months later TST = 23 mm of induration
• No symptoms of TB disease
• Normal CXR, CBC, AST, and bilirubin
Case 3
Questions
1. What are the patient’s risk factors 
for TB infection or disease?
2. Has the management of this patient 
to date been appropriate?
Case 3
Discussion of risk factors
• Patient is a contact of an infectious TB case
• Recent immigrant to the U.S. from a country 
with a high prevalence of TB. Such persons 
have increased rates of TB
• If the patient had not been a contact, the 
recent immigration (less than 4 years) would 
have made him a candidate for TB testing, 
but the 5-mm reaction would not be 
considered positive
Case 3
Discussion of management
• Should be treated for LTBI if TST reactions 
10 mm of induration
• As a contact of an active TB case, 5 mm of 
induration is considered positive
• This patient should have been treated for 
LTBI immediately after the first TST
Case 4
• 56-year-old White male
• Works in a mycobacteriology lab
• TST result negative 1 year ago
• M. marinum infection in his hand 8 months ago 
• TST result 5mm
• QFT-G test positive
• No symptoms of TB disease, CXR normal
• No known contact with a TB patient & no known 
spills or accidents in the lab
